Nova Eye Medical Limited
ELXMF
$0.10
-$0.086-46.24%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 27.47% | 30.44% | 50.64% | 46.93% | 19.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.47% | 30.44% | 50.64% | 46.93% | 19.75% |
| Cost of Revenue | 36.46% | 39.64% | 203.06% | 195.52% | 58.33% |
| Gross Profit | 23.31% | 26.19% | 38.71% | 35.29% | 7.65% |
| SG&A Expenses | 16.89% | 19.62% | 8.32% | 5.65% | -24.86% |
| Depreciation & Amortization | -- | -- | 30.54% | 27.36% | -- |
| Other Operating Expenses | 3.43% | 5.84% | 70.49% | 66.25% | 129.27% |
| Total Operating Expenses | 15.86% | 18.57% | 23.89% | 20.83% | 0.21% |
| Operating Income | 4.91% | 2.70% | 26.97% | 28.78% | 22.45% |
| Income Before Tax | 4.11% | 1.88% | 69.97% | 70.71% | 15.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.11% | 1.88% | 64.06% | 64.95% | 15.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.11% | 1.88% | 64.06% | 64.95% | 15.61% |
| EBIT | 4.91% | 2.70% | 26.97% | 28.78% | 22.45% |
| EBITDA | 4.68% | 2.45% | 47.27% | 48.57% | 12.01% |
| EPS Basic | 19.79% | 18.56% | 72.57% | 73.18% | 35.57% |
| Normalized Basic EPS | 20.00% | 18.33% | 45.45% | 46.43% | 35.48% |
| EPS Diluted | 19.79% | 18.56% | 72.57% | 73.18% | 35.57% |
| Normalized Diluted EPS | 20.00% | 18.33% | 45.45% | 46.43% | 35.48% |
| Average Basic Shares Outstanding | 20.38% | 20.38% | 31.00% | 31.00% | 30.78% |
| Average Diluted Shares Outstanding | 20.38% | 20.38% | 31.00% | 31.00% | 30.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |